v3.25.4
Condensed Consolidated Statements of Cash Flows - USD ($)
 6 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash flow from operating activities:    
Net Income (Loss) $ 1,296,306 $ (1,311,230)
Adjustment to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 632,491 618,328
Stock options expense 149,262 88,045
Restricted common stock expense 276,669 864,266
Adjustment to contingent earnout liability 596,603 2,406,886
Changes in operating assets and liabilities:    
Accounts receivable 1,530,063 (266,255)
Prepaid expenses and other current assets (127,818) (98,613)
Prepaid royalties (41,230) 478,169
Accounts payable and accrued expenses (1,035,903) (737,670)
Deferred revenue (785,267) (170,433)
Net cash provided by operating activities 2,491,176 1,871,493
Cash flow from investing activities:    
Purchase of property and equipment (24,561) (5,404)
Net cash used in investing activities (24,561) (5,404)
Cash flow from financing activities:    
Proceeds from the exercise of stock options 157,500  
Common stock repurchase (39,549) (205,278)
Payment of contingent acquisition consideration - Scite and FIZ (2,554,394) (62,560)
Net cash used in financing activities (2,436,443) (267,838)
Effect of exchange rate changes 5,296 2,873
Net increase in cash and cash equivalents 35,468 1,601,124
Cash and cash equivalents, beginning of period 12,227,312 6,100,031
Cash and cash equivalents, end of period 12,262,780 7,701,155
Supplemental disclosures of cash flow information:    
Cash paid for income taxes 30,090 61,406
Non-cash investing and financing activities:    
Contingent consideration accrual on asset acquisition 20,981 $ 30,198
Common stock issued for Scite earnout payment $ 1,453,428